Comvita
Comvita's Mānuka honey is four-factor tested to UMF standards whose trademark it co-created.
- Public company
- Paengaroa, NZNew Zealand
Comvita's Mānuka honey is four-factor tested to UMF standards whose trademark it co-created.
What is the investment case, and what must be true for it to hold?
Comvita can expand revenue through North American retail provided contribution on that growth recovers, while a global honey glut remains the main margin risk. North American sales climbed from NZD 28.7 million in FY25 to NZD 58.7 million in FY26, lifting the region's share of group revenue from 14.9% to 27.6%, but net contribution dropped from 14.1% to 6.6% during that expansion. The return to profit occurred amid a global honey glut that drove producer prices down.
Revenue for FY26 totaled $213 million, a 10.7 per cent rise from $192.4 million in FY25, supported by strong club retail results in North America. Gross margin climbed to 53.9% in FY26 from a normalized 50.8% in FY25.
Which risks could break the thesis, and what would warn of them?
Comvita's recovery still depends on whether North American growth turns into regional contribution and on whether producer prices stabilize. Sales in North America climbed from NZD 28.7 million in FY25 to NZD 58.7 million in FY26, though regional net contribution dropped from 14.1% to 6.6%. The company returned to profit in FY26 on revenue of $213.0 million, up 10.7 percent, and completed a $40.5 million capital raise and refinancing package.
A global oversupply of honey pushed prices down for producers in the wider honey sector.
What does the product do for its buyer, and how is it delivered?
Comvita's Mānuka blend MGO 30+ fills everyday table use as a spreadable honey, drawn from a natural blend of New Zealand honeys that includes honey from the Mānuka bush.
The Mānuka blend MGO 30+ is available from Comvita in the listed sizes of 250g and 500g.